Patients reported their assessments either directly during their appointment at our BoNT outpatient clinic or during the course of the following treatment cycle. The part intended for the physiotherapists was then completed during the patient’s next physiotherapy session. Our patients and their treating physiotherapists were asked to indicate the focus and most frequently applied exercises of the last physiotherapy sessions when answering the questions. The questionnaire consisted of the following parts:
The physiotherapists were asked to fill in the following information:
The CDQ-24, a CD-specific assessment of quality of life with a special focus on CD-related problems in daily living [17 (link)], was obtained as a patient self-rating. It consists of 24 single items within five domains: stigma (question 7, 8, 9, 10, 18 and 22); emotional well-being (question 11, 12, 13, 14 and 15); pain (question 4, 5 and 21); activities of daily living (question 1, 2, 3, 6, 19 and 20) and social/family life (question 16, 17, 23 and 24). Each item ranks between 0 and 4 points, a higher score means a higher disease severity. The maximum score is 100 points, with 0 being the best and 100 being the worst possible CD-related Quality of Life [18 (link)].
We collected the rating of the TWSTRS severity score [19 ] and the details on the last BoNT treatment from the electronic medical records. The following BoNT preparations were used: OnabotulinumtoxinA (Botox®, Allergan, AbbVie company, Ireland), AbobotulinumtoxinA (Dysport®, Ipsen Pharma, France) and IncobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals, Germany). To ensure comparability of the applied BoNT preparations, we used the following formula to calculate the equivalent dose for AbobotulinumtoxinA: 1 U OnaA or IncoA = 2.5 U AboA. This ratio showed similar efficacy and side effects according to a systematic literature review [20 (link)]. The TWSTRS was assessed in an unblinded manner prior to the injection of BoNT during the patients’ visit to our BoNT outpatient clinic.
The physiotherapists were asked to fill in the following information:
The CDQ-24, a CD-specific assessment of quality of life with a special focus on CD-related problems in daily living [17 (link)], was obtained as a patient self-rating. It consists of 24 single items within five domains: stigma (question 7, 8, 9, 10, 18 and 22); emotional well-being (question 11, 12, 13, 14 and 15); pain (question 4, 5 and 21); activities of daily living (question 1, 2, 3, 6, 19 and 20) and social/family life (question 16, 17, 23 and 24). Each item ranks between 0 and 4 points, a higher score means a higher disease severity. The maximum score is 100 points, with 0 being the best and 100 being the worst possible CD-related Quality of Life [18 (link)].
We collected the rating of the TWSTRS severity score [19 ] and the details on the last BoNT treatment from the electronic medical records. The following BoNT preparations were used: OnabotulinumtoxinA (Botox®, Allergan, AbbVie company, Ireland), AbobotulinumtoxinA (Dysport®, Ipsen Pharma, France) and IncobotulinumtoxinA (Xeomin®, Merz Pharmaceuticals, Germany). To ensure comparability of the applied BoNT preparations, we used the following formula to calculate the equivalent dose for AbobotulinumtoxinA: 1 U OnaA or IncoA = 2.5 U AboA. This ratio showed similar efficacy and side effects according to a systematic literature review [20 (link)]. The TWSTRS was assessed in an unblinded manner prior to the injection of BoNT during the patients’ visit to our BoNT outpatient clinic.
Free full text: Click here
